HUP0301828A2 - Apomorfin alkalmazása nemi mżködészavar meghatározott apomorfin-plazmakoncentrációval történż kezelésre szolgáló készítmények elżállítására - Google Patents

Apomorfin alkalmazása nemi mżködészavar meghatározott apomorfin-plazmakoncentrációval történż kezelésre szolgáló készítmények elżállítására

Info

Publication number
HUP0301828A2
HUP0301828A2 HU0301828A HUP0301828A HUP0301828A2 HU P0301828 A2 HUP0301828 A2 HU P0301828A2 HU 0301828 A HU0301828 A HU 0301828A HU P0301828 A HUP0301828 A HU P0301828A HU P0301828 A2 HUP0301828 A2 HU P0301828A2
Authority
HU
Hungary
Prior art keywords
apomorphine
production
sexual dysfunction
pharmaceutical compositions
plasma concentration
Prior art date
Application number
HU0301828A
Other languages
English (en)
Inventor
John Daniel Bollinger
Yisheng Chen
Pramod K. Gupta
Dennis Y. Lee
Thomas L. Reiland
Jack Yuqun Zheng
Original Assignee
Tap Pharmaceutical Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tap Pharmaceutical Products Inc. filed Critical Tap Pharmaceutical Products Inc.
Publication of HUP0301828A2 publication Critical patent/HUP0301828A2/hu
Publication of HUP0301828A3 publication Critical patent/HUP0301828A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

A találmány tárgyát apomorfin alkalmazása képezi, páciensek nemiműködészavarának kezelésére szolgáló gyógyászati készítményekelőállítására, mely készítmények alkalmazása esetén az apomorfin-kezelés nemkívánatos mellékhatásai csökkennek. A találmány szerintialkalmazással előállított készítmények alkalmazása esetén a páciensekplazmájában a kialakult apomorfin-koncentráció legfeljebb 10 ng/ml. Eza koncentráció a találmány szerinti alkalmazással előállítottkészítmények adagolásával előnyösen úgy érhető el, hogy a kezeltpáciensek kevesebb mint 15%-ában lép fel hányás. A találmány szerintialkalmazással előállított készítmények beadása orron át, belélegzésselvagy szájon át történhet. Ó
HU0301828A 2000-03-20 2001-03-14 Use of apomorphine for the production of pharmaceutical compositions for treating sexual dysfunction with apomorphine at specified plasma concentration levels HUP0301828A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19054000P 2000-03-20 2000-03-20
PCT/US2001/040294 WO2001074358A1 (en) 2000-03-20 2001-03-14 Methods for treating sexual dysfunction with apomorphine at specified plasma concentration levels

Publications (2)

Publication Number Publication Date
HUP0301828A2 true HUP0301828A2 (hu) 2003-09-29
HUP0301828A3 HUP0301828A3 (en) 2006-02-28

Family

ID=22701756

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0301828A HUP0301828A3 (en) 2000-03-20 2001-03-14 Use of apomorphine for the production of pharmaceutical compositions for treating sexual dysfunction with apomorphine at specified plasma concentration levels

Country Status (18)

Country Link
US (1) US20020006933A1 (hu)
EP (1) EP1265609A4 (hu)
JP (1) JP2003533441A (hu)
KR (1) KR20030012852A (hu)
CN (1) CN1315177A (hu)
AU (1) AU2001253854A1 (hu)
BG (1) BG107185A (hu)
BR (1) BR0005797A (hu)
CA (1) CA2403791A1 (hu)
CZ (1) CZ20023427A3 (hu)
HU (1) HUP0301828A3 (hu)
IL (1) IL151615A0 (hu)
MX (1) MXPA02009237A (hu)
NO (1) NO20024442L (hu)
PL (1) PL365854A1 (hu)
SK (1) SK15112002A3 (hu)
WO (1) WO2001074358A1 (hu)
ZA (1) ZA200207113B (hu)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6566368B2 (en) * 1994-04-22 2003-05-20 Pentech Pharmaceuticals, Inc. Apomorphine-containing dosage form for ameliorating male erectile dysfunction
SE0102036D0 (sv) * 2001-06-08 2001-06-08 Axon Biochemicals Bv Pharmaceutical formulation for the efficient administration of apomorphine, 6aR- (-) -N- Propyl- norapomorphine and their derivatives and pro-drugs thereof
MXPA03007081A (es) * 2001-02-08 2004-10-15 Pharmacia Corp Medicamento de accion rapida para el tratamiento de disfuncion sexual.
EP1340492A1 (en) * 2002-03-01 2003-09-03 CHIESI FARMACEUTICI S.p.A. Aerosol formulations for pulmonary administration of medicaments having systemic effects
US20040018237A1 (en) * 2002-05-31 2004-01-29 Perricone Nicholas V. Topical drug delivery using phosphatidylcholine
US7591999B2 (en) * 2003-03-04 2009-09-22 Mitsubishi Tanabe Pharma Corporation Powdery preparation for nasal administration
US20040204439A1 (en) * 2003-04-14 2004-10-14 Staniforth John Nicholas Composition, device, and method for treating sexual dysfunction via inhalation
CA2522231A1 (en) * 2003-04-14 2004-10-21 Vectura Ltd Pharmaceutical compositions comprising apomorphine for pulmonary inhalation
US20060147389A1 (en) * 2004-04-14 2006-07-06 Vectura Ltd. Devices and pharmaceutical compositions for enhancing dosing efficiency
GB0604319D0 (en) * 2006-03-03 2006-04-12 Optinose As Nasal delivery
GB2437488A (en) * 2006-04-25 2007-10-31 Optinose As Pharmaceutical oily formulation for nasal or buccal administration
GB0721394D0 (en) * 2007-10-31 2007-12-12 Vectura Group Plc Compositions for trating parkinson's disease
NZ612686A (en) 2010-12-16 2015-11-27 Cynapsus Therapeutics Inc Sublingual films
EP2545905A1 (en) * 2011-07-11 2013-01-16 Britannia Pharmaceuticals Limited A new therapeutical composition containing apomorphine as active ingredient
DK2854764T3 (en) * 2012-06-05 2019-04-08 Neuroderm Ltd COMPOSITIONS CONTAINING APOMORPHINE AND ORGANIC ACIDS, AND APPLICATIONS THEREOF
US20140377365A1 (en) * 2013-06-19 2014-12-25 Map Pharmaceuticals, Inc. Sustained-release formulation of rotigotine

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5472954A (en) * 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation
DE4321965A1 (de) * 1993-07-01 1995-01-12 Cytech Biomedical Inc Oxytocin-haltige Zusammensetzung sowie die Verwendung derselben als Mittel, insbesondere Nasenspray zur Behandlung sexueller Dysfunktionen
DE69831421T2 (de) * 1997-12-02 2006-06-22 Archimedes Development Ltd. Zusammensetzungen zur nasalen verabreichung
US5945117A (en) * 1998-01-30 1999-08-31 Pentech Pharmaceuticals, Inc. Treatment of female sexual dysfunction
MXPA01000275A (es) * 1998-06-22 2002-04-24 Univ Kingston Metodo y composiciones para el tratamiento o alivio de disfunciones sexuales femeninas.
US6436950B1 (en) * 1998-08-14 2002-08-20 Nastech Pharmaceutical Company, Inc. Nasal delivery of apomorphine
US5994363A (en) * 1998-08-24 1999-11-30 Pentech Pharmaceuticals, Inc. Amelioration of apomorphine adverse effects
US6291471B1 (en) * 1998-12-17 2001-09-18 Abb Holdings, Inc. Use of apomorphine for the treatment of organic erectile dysfunction in males

Also Published As

Publication number Publication date
BG107185A (bg) 2003-05-30
CZ20023427A3 (cs) 2003-11-12
US20020006933A1 (en) 2002-01-17
HUP0301828A3 (en) 2006-02-28
CA2403791A1 (en) 2001-10-11
AU2001253854A1 (en) 2001-10-15
CN1315177A (zh) 2001-10-03
KR20030012852A (ko) 2003-02-12
NO20024442D0 (no) 2002-09-17
EP1265609A1 (en) 2002-12-18
ZA200207113B (en) 2004-01-28
PL365854A1 (en) 2005-01-10
SK15112002A3 (sk) 2003-06-03
BR0005797A (pt) 2001-10-16
NO20024442L (no) 2002-11-20
EP1265609A4 (en) 2005-02-09
MXPA02009237A (es) 2004-04-05
JP2003533441A (ja) 2003-11-11
IL151615A0 (en) 2003-04-10
WO2001074358A1 (en) 2001-10-11

Similar Documents

Publication Publication Date Title
HUP0301828A2 (hu) Apomorfin alkalmazása nemi mżködészavar meghatározott apomorfin-plazmakoncentrációval történż kezelésre szolgáló készítmények elżállítására
MXPA05006572A (es) Composiciones y metodos para la administracion mejorada por via mucosa de peptidos fijadores al receptor de y2 y metodos para tratar y prevenir la obesidad.
BR0207024A (pt) Medicamento com ação inicial rápida para o tratamento de disfunção sexual
HUP0101268A2 (hu) A női nemi diszfunkció kezelésére alkalmas gyógyszerkészítmények
SG169233A1 (en) Pharmaceutical compositions comprising apomorphine for pulmonary inhalation
HK1177901A1 (en) Treatment of t-cell lymphoma using 10-propargyl-10-deazaaminopterin 10--10- t
CA2632207C (en) Use of calcitonin for the treatment of ra
CY1107262T1 (el) Θεραπεια της εξαρτησης στερησης
SG146648A1 (en) Pharmaceutical compositions for treating premature ejaculation by pulmonary inhalation
WO2006002096A3 (en) Low doses of l-citrulline for treating diseases
RU2007104774A (ru) Комбинация анти-вич ингибиторов обратной транскриптазы и протеазы
BRPI0415953A (pt) formulação de dosagem de liberação controlada oral, método de tratamento de um distúrbio, conjunto de formas de dosagem de liberação controlada e método para administração da formulação
MX2008001520A (es) Composiciones de tizanidina y metodos de tratamiento usando las composiciones.
NZ600803A (en) Recombinant human cc10 and compositions thereof for use in the treatment of nasal rhinitis
MXPA04003548A (es) Tratamiento de neumonia severa mediante administracion de inhibidor de via factor de tejido.
FR2863169B1 (fr) Medicament gazeux inhalable a base d'argon pour le traitement des neuro-intoxications
MX2013003523A (es) Composicion farmaceutica de dosis baja.
EA200700178A1 (ru) Пептид, обладающий стресспротекторным действием, фармацевтическая композиция на его основе и способ ее применения
RU2003127718A (ru) Применение флумазенила в производстве лекарственного средства для лечения кокаиновой зависимости
AR022116A1 (es) Terapia de combinacion para el vhc por induccion de ribavirina - interferon alfa
BR0212249A (pt) Composto, composição farmacêutica, método de tratamento ou profilaxia de doenças, e, uso de um composto
TW200626133A (en) Oral medication for twice-daily administration
UY27037A1 (es) Composición de apomorfina para tratar la disfunción sexual con niveles específicos de concentración en plasma
MD2327F1 (en) Method of treatment of parodontium affections
SG129278A1 (en) A solid oral dosage form of metformin and glyburide and the method of preparation thereof

Legal Events

Date Code Title Description
FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished